XML 32 R13.htm IDEA: XBRL DOCUMENT v3.25.2
Equity
 12 Months Ended
Jun. 30, 2025
Equity [Abstract]  
Equity

 7 Equity

 

(a) Share capital

  

      30 June
2025		   30 June
2024		   30 June
2023		   30 June
2025		   30 June
2024		   30 June
2023
   Notes  Shares   Shares       Shares   $   $   $
Ordinary shares                       
Ordinary Shares Fully paid      2,364,949,502    460,367,051    339,313,037    176,558,493    100,681,716   97,230,329
   7(a)(i)   2,364,949,502    460,367,051    339,313,037    176,558,493    100,681,716   97,230,329

 

(i) Movements in ordinary shares:

 

Details  Notes  Number of shares   Total
$		 
Balance at 1 July 2022         255,433,248    86,758,783 
Issue at $0.14 pursuant to institutional entitlement offer (2022-10-25)      39,878,805    5,583,033 
Issue of forfeiture shares at $0.171 (2022-10-26)      1,149,417    196,550 
Issue at $0.14 pursuant to rights issue (2022-11-25)      32,073,235    4,490,253 
Issue at $0.143 upon Pharma 15 acquisition (2023-03-03)      10,412,934    1,482,360 
Issue at $0.136 under employee incentive scheme (2023-04-28)      365,398    49,694 
Less: Transaction costs arising on share issues      -    (1,330,344)
              
Balance at 30 June 2023      339,313,037    97,230,329 
              
Balance at 1 July 2023      339,313,037    97,230,329 
Issue at $0.070 pursuant to rights issue (2023-12-08)      30,197,244    2,113,808 
Issue at $0.105 of forfeiture shares as per employment contract (2023-12-14)      2,128,815    223,526 
Issue of ordinary shares at $0.0864 in lieu of cash for services rendered (2024-01-05)      1,200,013    103,681 
Issue at $0.07 pursuant to rights issue shortfall (2024-01-31)      18,714,145    1,309,990 
Issue at $0.07 pursuant to rights issue shortfall (2024-02-09)      1,950,000    136,500 
Issue at $0.059 pursuant to Lind agreement (2024-02-14)      20,000,000    
-
 
Issue at $0.059 as part of Pharma15 acquisition (2024-03-04)      25,856,470    1,297,022 
Issue at $0.052 pursuant to Lind agreement (2024-03-12)      5,769,231    300,000 
Issue at $0.045 pursuant to Lind agreement (2024-04-15)      6,666,667    300,000 
Issue at $0.035 pursuant to Lind agreement (2024-05-16)      8,571,429    300,000 
Less: Transaction costs arising on share issues      
-
    (2,633,140)
Balance at 30 June 2024      460,367,051    100,681,716 
              
              
Balance at 1 July 2024      460,367,051    100,681,716 
Issue of ordinary shares at $0.040 pursuant to issue of securities(2024-07-01)      597,130,727    23,885,229 
Issue of ordinary shares at $0.040 pursuant to Tranche 2 placement shares (2024-08-21)      858,056,603    34,322,264 
Issue of ordinary shares at $0.040 pursuant to Tranche 2 placement shares (2024-08-21)      14,031,195    561,248 
Issue of ordinary shares at $0.050 pursuant to Lantheus investment (2024-08-23)      149,625,180    7,481,259 
Issue of ordinary shares at $0.040 pursuant to issue of placement shares (2024-09-13)      93,750,000    3,750,000 
Issue of ordinary shares at $0.036 pursuant to the achievement of a milestone (2024-12-13)      20,594,438    741,400 
Issue of ordinary shares at $0.036 pursuant to forfeiture shares (2024-12-16)      7,091,615    219,840 
Issue of ordinary shares at $0.060 pursuant to issue of placement shares to Lantheus (2025-01-20)      133,333,333    8,000,000 
Issue of ordinary shares at $0.025 pursuant to a milestone payment (2025-06-12)      30,969,360    774,234 
              
Less: Transaction costs arising on share issues      
-
    (3,858,697)
Balance at 30 June 2025      2,364,949,502    176,558,493 

(b) Other reserves

 

The following table shows a breakdown of the statement of financial position line item ‘other reserves’ and the movements in these reserves during the year and period, respectively. A description of the nature and purpose of each reserve is provided below the table.

 

      Shares to
be issued		   Share-based
payments		   Equity
settled
payments		   Foreign
currency
translation		   Total
other
reserves		 
   Notes  $   $   $   $   $ 
At 1 July 2022       
-
    6,554,312    573,865    (19,043)   7,109,134 
Currency translation differences       
-
    
-
    
-
    (728,250)   (728,250)
Other comprehensive loss       
-
    
-
    
-
    (728,250)   (728,250)
Transactions with owners in their capacity as owners                             
Issue of options as part of forfeiture payments       
-
    
-
    (136,454)   
-
    (136,454)
Issue of shares as part of forfeiture payments       
-
    
-
    (107,410)   
-
    (107,410)
Issue of options   7(b)(ii)   
-
    4,224,437    
-
    
-
    4,224,437 
                              
At 30 June 2023       
-
    10,778,749    330,001    (747,293)   10,361,457 
                              
                              
At 1 July 2023       
-
    10,778,749    330,001    (747,293)   10,361,457 
Currency translation differences       
-
    
-
    
-
    202,956    202,956 
Other comprehensive loss       
-
    
-
    
-
    202,956    202,956 
Transactions with owners in their capacity as owners                             
Issue of options as part of forfeiture payments       
-
    44,796    (44,796)   
-
    
-
 
Issue of shares as part of forfeiture payments       
-
    
-
    (147,038)   
-
    (147,038)
Issue of options   7(b)(ii)   
-
    3,327,468    
-
    
-
    3,327,468 
Shares to be issued       24,185,229    
-
    
-
    
-
    24,185,229 
At 30 June 2024       24,185,229    14,151,013    138,167    (544,337)   37,930,072 
                              
At 1 July 2024       24,185,229    14,151,013    138,167    (544,337)   37,930,072 
Currency translation differences       
-
    
-
    
-
    464,034    464,034 
Other comprehensive loss       24,185,229    14,151,013    138,167    (80,303)   38,394,106 
Transactions with owners in their capacity as owners                             
Transfer from Share-based payments to equity settled payments       
 
    (136,454)   136,454    
 
    
-
 
Issue of options as part of forfeiture payments       
-
    43,506    (43,506)   
-
    
-
 
Issue of shares as part of placement       (23,885,229)   
-
    
-
    
 
    (23,885,229)
Issue of shares as part of forfeiture payments       
-
    
-
    (200,394)   
-
    (200,394)
Lapse of forfeiture payment       
-
    
-
    (30,721)   
-
    (30,721)
Issue of options       
-
    2,157,778    
-
    
-
    2,157,778 
Cancellation of shares to be issued relating to Lind       (300,000)   
-
    
-
    
-
    (300,000)
Expiration of options       
-
    (2,797,451)   
-
    
-
    (2,797,451)
Forfeiture of options       
-
    (221,170)   
-
    
-
    (221,170)
At 30 June 2025       
-
    13,197,222    
-
    (80,303)   13,116,919 

(i) Nature and purpose of other reserves

 

Shares to be issued

 

Share coded as shares to be issued were issued on 1 July 2024 as part of the capital raise announced in June 2024.

 

Share-based payments

 

The share-based payment reserve records items recognized as expenses on valuation of share options issued to key management personnel, other employees and eligible contractors.

 

(i) Nature and purpose of other reserves (continued)

 

Foreign currency translations

 

Exchange differences arising on translation of foreign controlled entities are recognized in other comprehensive income or loss as described in note 20(c) and accumulated in a separate reserve within equity. The cumulative amount is reclassified to profit or loss when the net investment is disposed of.

 

Equity settled payments

 

Equity settled payments reserve records items recognized as expenses on valuation of shares to be issued to key management personnel and other employees for forfeiture of long term incentives at previous employers.

 

(ii) Movements in options:

 

Details   Number of
options		     Total
$		  
Balance at 1 July 2022     41,553,372       6,554,312  
Issue of listed options     79,352,040       493,580  
Issue of ESOP unlisted options     32,804,903       1,859,699  
Forfeiture of ESOP unlisted options     (2,000,000 )     (136,454 )
Expense for share-based payments for options previously issued    
-
       1,871,158  
                 
Balance at 30 June 2023     151,710,315       10,642,295  
Issue of unlisted options*     16,455,224       763,778  
Issue of ESOP unlisted options     18,795,456       742,379  
Expense for share-based payments for options previously issued    
-
       1,866,107  
                 
Balance at 30 June 2024     186,960,995       14,014,559  
Issue of unlisted options     968,815,574       29,985  
Issue of ESOP unlisted options     164,472,155       1,396,110  
Forfeiture of options     (4,351,176 )     (221,170 )
Expiration of options     (163,605,052 )     (2,797,451 )
Expense for share-based payments for options previously issued    
-
       775,189  
Balance at 30 June 2025     1,152,292,496       13,197,222  

 

*The above number has been updated to include an additional 8,955,224 options valued at $343,028 that was not included in the table in prior years report.

(c) Other equity

 

   30 June   30 June   30 June 
   2025
$		   2024
$		   2023
$		 
Contingent issue of equity   849,544    849,544    849,544 
Deferred issue of equity   
-
    
-
    1,297,022 
    849,544    849,544    2,146,566 

 

Contingent issue of equity includes amounts related to the value of consideration shares to be issued to the Pharma15 shareholders once certain milestones are met as per their agreement. For more information, please refer to note 13(g).